At the American Association for Clinical Chemistry meeting, Theranos CEO Elizabeth Holmes said her company is working on third-party review and publications of the firm's technologies and tests.
Researchers led by MIT's Jim Collins have built upon their paper-based Ebola test and are hoping to find a partner to help scale production and manufacturing of the test.
The company plans to add assays for Group B Streptococcus, Clostridium difficile, and norovirus in 2016 to complement its existing meningitis test.
The test is the first in the Dublin, Ireland-based firm's pipeline of infectious disease assays that use loop-mediated isothermal amplification.
Lumora's MDx technology for the clinical and industrial sectors will be merged with ERBA Mannheim's IVD testing business in a wide range of market segments.
The 3M Molecular Detection Assay 2 – Listeria monocytogenes is 30 percent faster than the first-generation test.
Meridian's Diagnostics segment grew 2 percent lifted by a 10 percent increase in revenues from the illumigene molecular product line.
The assay is the first on the firm's isothermal nucleic acid amplification-based platform.
At AGBT, the firm discussed the launch of the Proton PII chip, an update of the PI chip, and sample prep improvements.
The platform — called NINA for non-instrumented nucleic acid amplification — is designed to work with a wide range of isothermal amplification methods.
In PLOS this week: Mycobacterium abscessus linked to gastric conditions, placental gene expression changes associated with preterm birth, and more.
The Guardian reports that UK universities are looking into ways to reduce labs' reliance on single-use plastics.
People with certain gene variants tend to not like vegetables, particularly bitter ones, CNN reports.
MIT's Technology Review reports on a company's genetic test that gauges an embryo's susceptibility to certain diseases.